US-based medical device company St. Jude Medical has completed the acquisition of NeuroTherm for $200m.
NeuroTherm is a manufacturer of interventional pain management therapies.
NeuroTherm has expertise in the treatment of spinal pain by using radiofrequency ablation (RFA), a segment of the chronic pain market in which St. Jude is not present.
RFA is a minimally invasive procedure, which is developed to reduce back pain by interrupting the nerve supply from painful facet joints in the neck or back.
NeuroTherm offers multi-lesion RF generator, which allows real-time temperature monitoring and enables continuous delivery of energy to each site designed to ensure complete treatment of each targeted spinal nerve.
The firm’s products are sold in around 65 countries.
St. Jude Medical chief operating officer Michael Rousseau said the acquisition further demonstrates firm’s commitment to chronic pain program and steadfast focus on improving patient outcomes.
"Over the last year, we have launched two novel neuromodulation products, made a strategic investment in Spinal Modulation, and initiated two multi-center, randomized clinical studies to evaluate alternatives for patients living with chronic pain," Rousseau added.
St. Jude Medical manufactures chronic pain product portfolio, which provides both radiofrequency ablation for spinal pain and spinal cord stimulation.